Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
KMTS · Nasdaq · United States · Surgical & Medical Instruments & Apparatus
In shortKESTRA MEDICAL TECHNOLOGIES, LTD. is loss-making, burns cash and holds more cash than debt, with revenue growing (+59.0% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -141.6% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -138.4% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -56.6% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -35.2% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 4.41× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.16× | 100/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | -17.86× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | -2.55 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -122.6% | 0/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 0 of 3 | 0/100 |
Weight in the score: 20%
| Profitable years (last 5) | 0 of 3 | 0/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 2 | 100/100 |
| Revenue growth volatility | 39.6% | 0/100 |
| Operating margin volatility | 86.3% | 0/100 |
Weight in the score: 20%
Fiscal year 2026 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
The last 3 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 28 | 60 | 95 |
| Cost of revenue | 27 | 36 | 46 |
| Gross profit | 0.4 | 24 | 49 |
| Research & development | 15 | 16 | 19 |
| Selling, general & admin | 70 | 115 | 164 |
| Operating income | (85) | (106) | (135) |
| Interest expense | 6.2 | 7.7 | 7.5 |
| Pre-tax income | (94) | (114) | (131) |
| Income tax | 0 | 0.1 | 0.3 |
| Net income | (94) | (114) | (132) |
| Diluted EPS | −$5.07 | −$5.13 | −$2.43 |
| Diluted shares (millions) | 20 | 25 | 54 |
−2.55 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
5/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice.
Latest annual report: Jul 31, 2026 · Data updated Sep 14, 2026